Advanced imaging of skeletal manifestations of systemic mastocytosis

Fritz, Jan; Fishman, Elliot K.; Carrino, John A.; Horger, Marius

doi:10.1007/s00256-012-1374-9

Cited by 27 publications

(10 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In solid tumours, it is well established that beyond the tumour glucose consumption, tumour infiltrating inflammatory cells also participate in FDG uptake [16]. In mastocytosis, FDG uptake could be due to activated mast cells themselves, AHNMD-related tumour cells, osteoblastic activation in the case of bone condensing type lesions and medullar regeneration [17]. Our results, including the absence of marked pathological uptake in the purely aggressive form of SM (ASM), suggest that mast cell activation and infiltration are not well delineated by FDG-PET.…”

Section: Discussionmentioning

confidence: 99%

FDG-PET/CT findings in systemic mastocytosis: a French multicentre study

Djelbani-Ahmed

Chandesris

Mékinian

et al. 2015

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

FDG uptake does not appear to be a sensitive marker of mast cell activation or proliferation because no significant FDG uptake was observed in most common forms of mastocytosis (notably purely aggressive SM). However, pathological FDG uptake was observed in the SM-AHNMD and in MCS cases, suggesting a role of FDG-PET in their early identification and as a tool of therapeutic assessment in this subgroup of patients.

show abstract

Section: Discussionmentioning

confidence: 99%

FDG-PET/CT findings in systemic mastocytosis: a French multicentre study

Djelbani-Ahmed

Chandesris

Mékinian

et al. 2015

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“… 11 , 12 However, when such lesions are radiologically identified, final diagnosis remains extremely challenging since they resemble osteopoikilosis or metastases. 13 , 14 Osteopoikilosis is an asymptomatic bone dysplasia characterized by numerous bony islands typically clustered around joints within the meta-epiphyseal regions, carpal and tarsal bones, the pelvic ring, and scapulae. It is usually asymptomatic, often discovered incidentally during radiographic examinations made for other reasons, and normally does not demonstrate radiotracer uptake on bone scintigraphy, contrary to what usually occurs in metastasis.…”

Section: Imaging Findingsmentioning

confidence: 99%

Systemic Mastocytosis: Radiological Point of View

Leone

Macagnino

D’Ambra

et al. 2021

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Radiological diagnosis of systemic mastocytosis (SM) can be hard to establish. This is mainly due to the variable radiological features involving many organ systems (e.g., respiratory, cardiovascular, lympho-reticular, digestive systems, and most commonly skin), and the broad spectrum of skeletal findings, in particular. Skeletal involvement is the most common and prominent imaging feature in patients with SM and represents a prognostic factor as it may entail an aggressive course of the disease. Diagnosis, which is largely established by histological evaluation of a bone marrow trephine biopsy specimen supplemented by imaging modalities such as radiography, CT, and magnetic resonance imaging, requires a team approach between the hematologist, radiologist, and pathologist. The general radiologist needs to be familiar with the imaging findings because they may be the first to suggest the correct diagnosis. The primary purposes of this article were to equip clinicians with pertinent radiological semiotics and present relevant radiological features that assist early diagnosis and selection of an effective treatment.

show abstract

“…On the other hand, SM-associated bone disease is thought to manifest due to the release of various mast cell mediators including histamine, proteases, and heparin among others. These can manifest with a number of skeletal patterns on radiographic studies including osteopenia and osteoporosis, and ranging from lytic to sclerotic changes [25]. Thus, thorough radiographic examination of the pattern of bone disease can help differentiate the underlying cause.…”

Section: Discussionmentioning

confidence: 99%

Systemic mastocytosis with renal light chain amyloidosis: associated non-mast cell disorder or concurrent disease

et al. 2019

View full text Add to dashboard Cite

Systemic mastocytosis with an associated hematological neoplasm (SM-AHN) is a rare diagnosis commonly associated with myeloid disorders. Herein, we describe the case of a 53-year-old female diagnosed with systemic mastocytosis (SM) in conjunction with renal light chain amyloidosis (AL) and smoldering myeloma. Although cytokines such as IL-6 may play a role in the proliferation of plasma cells, delays in the diagnosis of SM and paucity of relevant studies cast uncertainty on whether the associated disease is secondary to the mast cells or etiologically independent. To our knowledge, this is the first case of confirmed renal AL disease in conjunction with SM. We review and summarize the available literature describing SM in association with plasma cell disorders.

show abstract

Advanced imaging of skeletal manifestations of systemic mastocytosis

Cited by 27 publications

References 59 publications

FDG-PET/CT findings in systemic mastocytosis: a French multicentre study

FDG-PET/CT findings in systemic mastocytosis: a French multicentre study

Systemic Mastocytosis: Radiological Point of View

Systemic mastocytosis with renal light chain amyloidosis: associated non-mast cell disorder or concurrent disease

Contact Info

Product

Resources

About